DC89101 · Updated 28 October 2026
C12-4 / A4 (C12-494)
Instructions for Use
Before use
Check the supplied lot number, batch COA, approved SDS, quantity and retest date. Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
For small quantities of viscous or oily lipid, volumetric transfer can reduce weighing losses. Confirm solvent compatibility and solubility before preparing a stock; calculated volumes do not establish solubility.
Stock-solution planning
Volume (mL) = mass (mg) × 1000 / [molecular weight × concentration (mM)].
| Mass | 10 mM | 20 mM |
|---|---|---|
| 10 mg | 0.8163 mL | 0.4081 mL |
| 25 mg | 2.0407 mL | 1.0204 mL |
| 50 mg | 4.0815 mL | 2.0407 mL |
| 100 mg | 8.1630 mL | 4.0815 mL |
Literature formulation reference
| Component | DC Chemicals product | Molecular weight | Molar ratio | Mass at 1 µmol total lipid (mg) |
|---|---|---|---|---|
| A4 / C12-494 | DC89101 | 1225.04 | 35 | 0.428764 |
| DOPE | Not uniquely mapped | 744.03 | 16 | 0.119045 |
| Cholesterol | DCD-041 | 386.65 | 46.5 | 0.179792 |
| C14-PEG2000 (14:0 PEG2000 PE) | Not uniquely mapped | Not established | 2.5 | Not calculable from disclosed data |
Standard formulation described in companion patent WO2024081715A2, Materials and Methods, LNP formulation: 35:16:46.5:2.5 molar. Ionizable lipid:mRNA is 10:1 by weight; it is not N/P. C14-PEG2000 PE is not assumed to be DMG-PEG2000. PEG-component MW and commercial mapping remain unassigned.
Read the complete study conditions, biological results, tolerability and figures →